AXAL

May 19, 2017

Cervical Cancer Patient Achieves Long-lasting Response to AXAL in Clinical Trial

News

One of nine cervical cancer patients treated with AXAL achieved a long-lasting partial response to the therapy, according to a Phase 1 study. The treatment’s maker, Advaxis, presented the results in a ... Read more

May 10, 2017

Erin Andrews, the Dancing with the Stars Host, Will Be Special Guest at Cervical Cancer Forum

News

Erin Andrews, a cervical cancer survivor who is the host of ABC Television’s “Dancing with the Stars” program, will be a special guest at the Advaxis-sponsored Cervical Cancer Educational Forum in Hollywood, ... Read more

April 12, 2017April 12, 2017

Higher Doses of AXAL Vaccine Are Safe, Effective in Certain Types of Cervical Cancer, Says Advaxis

News

A recent trial showed the anti-cancer vaccine axalimogene filolisbac, also known as ADXS11-001 or AXAL, to be well tolerated at higher doses, with promising results against persistent or recurrent metastatic ... Read more

March 10, 2017

Advaxis to Provide Updates on Cervical Cancer Trial Program at Research Reception

News

Advaxis will host a research reception at the Society of Gynecologic Oncology’s 48th Annual Meeting on Women’s Cancer to provide an overview and updates of its cervical cancer clinical trial program. According ... Read more

February 27, 2017

Advaxis’ Trial Data on Metastatic Cervical Cancer Vaccine to Be Presented at SGO Meeting

News

Advaxis will present data from its Phase 2 clinical trial evaluating a new vaccine therapy, axalimogene filolisbac, for the treatment of metastatic cervical cancer at the Society of Gynecologic Oncology’s ... Read more

February 8, 2017

First Doses of AXAL Administered to Phase 3 Cervical Cancer Trial Participants

News

The first doses of Advaxis‘ axalimogene filolisbac, or AXAL, have been administered to women with advanced cervical cancer in a Phase 3 trial of the treatment’s effectiveness after chemotherapy and radiation. The multicenter, ... Read more

November 14, 2016

Early Trial Data of Axal Combo Therapy for HPV-linked Cervical Cancer Presented by Advaxis

News

Advaxis recently presented new data demonstrating the clinical benefit of Axal, its lead immunotherapy candidate, both as a single therapy and in combination with other immunotherapies, for patients with HPV-associated cervical cancer. ... Read more

November 9, 2016

Advaxis Begins Phase 3 Study of AXAL for Advanced Cervical Cancer

News

Advaxis has begun its Phase 3 clinical trial evaluating axalimogene filolisbac, or AXAL, administered in the adjuvant setting following chemotherapy and radiation in women with high-risk, locally advanced cervical cancer. ... Read more

July 13, 2016July 13, 2016

Phase 3 Study of Drug Candidate for Cervical Cancer Granted FDA Special Protocol Assessment

News

The U.S. Food and Drug Administration (FDA) has granted clinical stage biotechnology company Advaxis special approval for a Phase 3 clinical trial to evaluate the safety and effectiveness of the company’s lead ... Read more